Is anti-NMDA receptor encephalitis real? I. Diagnostic challenges

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

After conducting a thorough analysis of clinical, neurophysiological, neuroimmunological, neurobiological, and neuropathological research findings, the authors of the review question on the validity of the anti-NMDA receptor encephalitis concept. The review highlights the significance of studying sanogenetic mechanisms in medicine and warns against hasty interpretations of neurobiological data without clinical knowledge.

About the authors

Evgenii V. Snedkov

Psychiatric Hospital of St. Nicholas the Wonderworker

Email: esnedkov@mail.ru
ORCID iD: 0000-0002-1438-1890
SPIN-code: 4353-6428

M.D., D. Sci. (Med.), Prof., Psychiatrist

Russian Federation, Saint Petersburg

Igor A. Volchek

Federal State Budgetary Educational Institution of Higher Education Russian Biotechnological University; Research Center for Immunology and Allergology

Email: igor.volchek@gmail.com
ORCID iD: 0009-0000-1451-6145
SPIN-code: 6743-2105

M.D., D. Sci. (Med.), Prof. of the Department of Skin and Venereal Diseases with a Cosmetology Course of the Medical Institute of Continuing Education of the Federal State Budgetary Educational Institution of Higher Education “Russian Biotechnological University (ROSBIOTECH)”; Chief Researcher of the Research Center for Immunology and Allergology

Russian Federation, Moscow; Moscow

Ilia V. Lemeshev

Psychiatric Hospital of St. Nicholas the Wonderworker; North-Western State Medical University named after I.I. Mechnikov

Author for correspondence.
Email: ilya.lemeshev@gmail.com
ORCID iD: 0009-0002-0491-6545
SPIN-code: 7635-4548

M.D., Head of the Day Hospital Department, Psychiatrist; Assistant Professor at the Department of Psychiatry and Narcology

Russian Federation, Saint Petersburg; Saint Petersburg

References

  1. Bell LV. On a form of disease resembling some advanced stages of mania and fever, but so contradistinguished from any ordinarily observed or described combination of symptoms, as to render it probable that it may be an overlooked and hitherto unrecorded malady. Am J Insanity. 1849;6(2):97–127.
  2. Leongard K. Sistematika endogennykh psikhozov i ikh differentsirovannaya etiologiya. Per. s nem. pod red. A.S. Tiganova. M.: Prakticheskaya meditsina; 2010. 456 р. (In Russ)
  3. Kleist K. Die klinische Stellung der Motilitätspsychosen. Zeitschrift für die gesamte Neurologie und Psychiatrie. 1911;3:914–917.
  4. Franzek E, Beckmann H. Season-of-birth effect reveals the existence of etiologically different groups of schizophrenia. Biol Psychiatry. 1992;32(4):375–378. doi: 10.1016/0006-3223(92)90042-x.
  5. Stöber G, Franzek E, Beckmann H. The role of maternal infectious diseases during pregnancy in the etiology of schizophrenia in offspring. European Psychiatry. 1992;7(4):147–152. doi: 10.1017/S0924933800005241.
  6. Stöber G, Kocher I, Franzek E, Beckmann H. First-trimester maternal gestational infection and cycloid psychosis. Acta Psychiatr Scand. 1997;96(5):319–324. doi: 10.1111/j.1600-0447.1997.tb09923.x.
  7. Al-Haddad BJS, Oler E, Armistead B et al. The fetal origins of mental illness. Am J Obstet Gynecol. 2019;221(6):549–562. doi: 10.1016/j.ajog.2019.06.013.
  8. Massrali A, Adhya D, Srivastava DP et al. Virus-induced maternal immune activation as an environmental factor in the etiology of autism and schizophrenia. Front Neurosci. 2022;16:834058. doi: 10.3389/fnins.2022.834058.
  9. Ratnayake U, Quinn T, Walker DW, Dickinson H. Cytokines and the neurodevelopmental basis of mental illness. Front Neurosci. 2013;7:180. doi: 10.3389/fnins.2013.00180.
  10. Vasistha NA, Pardo-Navarro M, Gasthaus J et al. Maternal inflammation has a profound effect on cortical interneuron deve-lopment in a stage and subtype-specific manner. Mol Psychiatry. 2020;25(10):2313–2329. doi: 10.1038/s41380-019-0539-5.
  11. Seckl JR, Holmes MC. Mechanisms of disease: Glucocorticoids, their placental metabolism and fetal ‘programming’ of adult pathophysiology. Nat Clin Pract Endocrinol Metab. 2007;3(6):479–488. doi: 10.1038/ncpendmet0515.
  12. Lee YH, Cherkerzian S, Seidman LJ et al. Maternal bacterial infection during pregnancy and offspring risk of psychotic disorders: Variation by severity of infection and offspring sex. Am J Psychiatry. 2020;177(1):66–75. doi: 10.1176/appi.ajp.2019.18101206.
  13. Allswede DM, Yolken RH, Buka SL et al. Cytokine concentrations throughout pregnancy and risk for psychosis in adult offspring: A longitudinal case-control study. The Lancet Psychiatry. 2020; 7(3):254–261. doi: 10.1016/S2215-0366(20)30006-7.
  14. Cheslack-Postava K, Brown AS. Prenatal infection and schizophrenia: A decade of further progress. Schizophr Res. 2022;247:7–15. doi: 10.1016/j.schres.2021.05.014.
  15. Malhotra S, Sahoo S, Balachander S. Acute and transient psychotic disorders: Newer understanding. Curr Psychiatry Rep. 2019;21(11):113. doi: 10.1007/s11920-019-1099-8.
  16. Dalmau J, Armangué T, Planagumà J et al. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. Lancet Neurol. 2019;18(11):1045–1057. doi: 10.1016/S1474-4422(19)30244-3.
  17. Davies C, Segre G, Estradé A et al. Prenatal and perinatal risk and protective factors for psychosis: A systematic review and meta-analysis. Lancet Psychiatry. 2020;7(5):399–410. doi: 10.1016/S2215-0366(20)30057-2.
  18. Zimmer A, Youngblood A, Adnane A et al. Prenatal exposure to viral infection and neuropsychiatric disorders in offspring: A review of the literature and recommendations for the COVID-19 pandemic. Brain Behav Immun. 2021;91:756–770. doi: 10.1016/j.bbi.2020.10.024.
  19. Hansen N, Luedecke D, Malchow B et al. Autoantibody-associated psychiatric syndromes in children: Link to adult psychiatry. J Neural Transm. 2021;128:735–747. doi: 10.1007/s00702-021-02354-8.
  20. Pröbstel AK, Zamvil SS. Do maternal anti-N-methyl-D-aspartate receptor antibodies promote development of neuropsychiatric disease in children? Ann Neurol. 2019;86(5):653–655. doi: 10.1002/ana.25584.
  21. Tcakhilova SG, Kuznetsov VP, Khmelnitskaya AV et al. The influence of the immune status of the mother on fetal development and the health of the newborn (a review). Russian Journal of Human Reproduction. 2016;22(6):38–43. (In Russ). doi: 10.17116/repro201622638-43.
  22. Prüss H. Autoantibodies in neurological disease. Nat Rev Immunol. 2021;21:798–813. doi: 10.1038/s41577-021-00543-w.
  23. Ehrenreich H. Autoantibodies against N-methyl-D-aspartate receptor 1 in health and disease. Curr Opin Neurol. 2018;31(3):306–312. doi: 10.1097/WCO.0000000000000546.
  24. Gastaldi VD, Wilke JB, Weidinger CA et al. Factors predisposing to humoral autoimmunity against brain-antigens in health and disease: Analysis of 49 autoantibodies in over 7000 subjects. Brain Behav Immun. 2022;108:135–147. doi: 10.1016/j.bbi.2022.10.016.
  25. Hansen N. NMDAR autoantibodies in psychiatric disease — an immunopsychiatric continuum and potential predisposition for disease pathogenesis. J Transl Autoimmun. 2022;5:100165. doi: 10.1016/j.jtauto.2022.100165.
  26. Wilke JBH, Hindermann M, Berghoff SA et al. Autoantibodies against NMDA receptor 1 modify rather than cause encephalitis. Mol Psychiatry. 2021;26:7746–7759. doi: 10.1038/s41380-021-01238-3.
  27. Dahm L, Ott C, Steiner J et al. Seroprevalence of autoantibodies against brain antigens in health and disease. Ann Neurol. 2014;76(1):82–94. doi: 10.1002/ana.24189.
  28. Ehrenreich H. Autoantibodies against the N-methyl-D-aspartate receptor subunit NR1: Untangling apparent inconsistencies for clinical practice. Front Immunol. 2017;8:181. doi: 10.3389/fimmu.2017.00181.
  29. Hopfner F, Müller SH, Steppat D et al. No association between Parkinson disease and autoantibodies against NMDA-type glutamate receptors. Transl Neurodegener. 2019;8:11. doi: 10.1186/s40035-019-0153-0.
  30. Pan H, Oliveira B, Saher G et al. Uncoupling the widespread occurrence of anti-NMDAR1 autoantibodies from neuropsychiatric disease in a novel autoimmune model. Mol Psychiatry. 2019;24(10):1489–1501. doi: 10.1038/s41380-017-0011-3.
  31. Pan H, Steixner-Kumar AA, Seelbach A et al. Multiple inducers and novel roles of autoantibodies against the obligatory NMDAR subunit NR1: A translational study from chronic life stress to brain injury. Mol Psychiatry. 2021;26(6):2471–2482. doi: 10.1038/s41380-020-0672-1.
  32. Pollak TA, Kempton MJ, Iyegbe C et al. Clinical, cognitive and neuroanatomical associations of serum NMDAR autoantibodies in people at clinical high risk for psychosis. Mol Psychiatry. 2021;26(6):2590–2604. doi: 10.1038/s41380-020-00899-w.
  33. Lennox BR, Palmer-Cooper EC, Pollak T et al. Prevalence and clinical characteristics of serum neuronal cell surface antibodies in first-episode psychosis: A case-control study. Lancet Psychiatry. 2017;4(1):42–48. doi: 10.1016/S2215-0366(16)30375-3.
  34. Dalmau J, Tüzün E, Wu H et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Annals of Neurology. 2007;61(1):25–36. doi: 10.1002/ana.21050.
  35. Vitaliani R, Mason W, Ances B et al. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Annals of Neurology. 2005;58(4):594–604. doi: 10.1002/ana.20614.
  36. Dalmau J, Lancaster E, Martinez-Hernandez E et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10(1):63–74. doi: 10.1016/S1474-4422(10)70253-2.
  37. Gabilondo I, Saiz A, Galán L et al. Analysis of relapses in anti-NMDAR encephalitis. Neurology. 2011;77(10):996–999. doi: 10.1212/WNL.0b013e31822cfc6b.
  38. Armangue T, Spatola M, Vlagea A et al. Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: A prospective observational study and retrospective analysis. Lancet Neurol. 2018;17(9):760–772. doi: 10.1016/S1474-4422(18)30244-8.
  39. Phillips O, Tubre T, Lorenco H et al. Limbic encephalitis in a child with ovarian teratoma and influenza B. Case report and criti-cal review of the history of autoimmune anti-N-methyl-D-aspartate receptor encephalitis. J Neuroimmunol. 2021;360:577716. doi: 10.1016/j.jneuroim.2021.577716.
  40. Nabizadeh F, Balabandian M, Sodeifian F et al. Autoimmune encephalitis associated with COVID-19: A systematic review. Mult Scler Relat Disord. 2022;62:103795. doi: 10.1016/j.msard.2022.103795.
  41. Samim MM, Dhar D, Goyal S et al. AI-CoV study: autoimmune encephalitis associated with COVID-19 and its vaccines — a systematic review. J Clin Neurol. 2022;18(6):692–710. doi: 10.3988/jcn.2022.18.6.692.
  42. Martin S, Azzouz B, Morel A, Trenque T. Anti-NMDA receptor encephalitis and vaccination: A disproportionality analysis. Front Pharmacol. 2022;13:940780. doi: 10.3389/fphar.2022.940780.
  43. Valdoleiros SR, Calejo M, Marinho A et al. First report of concomitant cryptococcal meningitis and anti-NMDAR encephalitis. Brain Behav Immun Health. 2020;2:100036. doi: 10.1016/j.bbih.2020.100036.
  44. Zrzavy T, Endmayr V, Bauer J et al. Neuropathological variability within a spectrum of NMDAR-encephalitis. Ann Neurol. 2021;90(5):725–737. doi: 10.1002/ana.26223.
  45. Doden T, Sekijima Y, Ikeda J et al. Postpartum Anti-N-methyl-D-aspartate receptor encephalitis: A case report and lite-rature review. Intern Med. 2017;56(3):357–362. doi: 10.2169/internalmedicine.56.7442.
  46. Konen FF, Schwenkenbecher P, Jendretzky KF et al. Severe anti-N-methyl-D-aspartate receptor encephalitis under immunosuppression after liver transplantation. Front Neurol. 2019; 10:987. doi: 10.3389/fneur.2019.00987.
  47. Obi CA, Thompson E, Mordukhaev L et al. Anti-N-methyl-D-aspartate receptor encephalitis triggered by emotional stress. Proc (Bayl Univ Med Cent). 2019;32(4):605–606. doi: 10.1080/08998280.2019.1647713.
  48. Auriti C, De Rose DU, Santisi A et al. Pregnancy and viral infections: Mechanisms of fetal damage, diagnosis and prevention of neonatal adverse outcomes from cytomegalovirus to SARS-CoV-2 and Zika virus. Biochim Biophys Acta Mol Basis Dis. 2021;1867(10):166198. doi: 10.1016/j.bbadis.2021.166198.
  49. Teller J, Jung C, Wilke JBH et al. Autoantibodies against NMDAR subunit NR1 disappear from blood upon anesthesia. Brain Behav Immun Health. 2022;24:100494. doi: 10.1016/j.bbih.2022.100494.
  50. Kayser MS, Titulaer MJ, Gresa-Arribas N, Dalmau J. Frequency and characteristics of isolated psychiatric episodes in anti-N-methyl-D-aspartate receptor encephalitis. JAMA Neurol. 2013;70(9):1133–1139. doi: 10.1001/jamaneurol.2013.3216.
  51. Wu CY, Wu JD, Chen CC. The association of ovarian teratoma and anti-N-methyl-D-aspartate receptor encephalitis: An updated integrative review. Int J Mol Sci. 2021;22(20):10911. doi: 10.3390/ijms222010911.
  52. Vasenina EE, Levin OS, Gankina OA et al. Autoimmune anti-NMDA-R encephalitis. Zhurnal Nevrologii i Psikhiatrii. 2017;117(2):110-116. (In Russ). doi: 10.17116/jnevro201711721110-116.
  53. Shmukler AB, Ivashkina AA, Murashko AA. A case of anti-NMDA-receptor encephalitis presenting as febrile catatonia. Bulletin of Siberian Medicine. 2019;18(4):266–272. doi: 10.20538/1682-0363-2019-4-266-272.
  54. Giné Servén E, Boix Quintana E, Martínez Ramírez M et al. Cycloid psychosis as a psychiatric expression of anti-NMDAR encephalitis. A systematic review of case reports accomplished with the authors’ cooperation. Brain Behav. 2021;11(2):e01980. doi: 10.1002/brb3.1980.
  55. Komagamine T, Kanbayashi T, Suzuki K et al. “Atypical psychoses” and anti-NMDA receptor encephalitis: A review of literature in the mid-twentieth century. Psychiatry Clin Neurosci. 2022;76(2):62–63. doi: 10.1111/pcn.13317.
  56. Foucher JR, Bartsch AJ, Mainberger O et al. Parakinesia: A Delphi consensus report. Schizophr Res. 2022:S0920-9964(22)00366-8. doi: 10.1016/j.schres.2022.09.024.
  57. Giné Servén E, Boix Quintana E, Guanyabens Buscà N et al. Considerations of psychotic symptomatology in anti-NMDA encephalitis: Similarity to cycloid psychosis. Clin Case Rep. 2019;7(12):2456–2461. doi: 10.1002/ccr3.2522.
  58. Warren N, O’Gorman C, McKeon G et al. Psychiatric management of anti-NMDAR encephalitis: A cohort analysis. Psychol Med. 2021;51(3):435–440. doi: 10.1017/S0033291719003283.
  59. McKeon GL, Robinson GA, Ryan AE et al. Cognitive outcomes following anti-N-methyl-D-aspartate receptor encephalitis: A systematic review. J Clin Exp Neuropsychol. 2018;40(3):234–252. doi: 10.1080/13803395.2017.1329408.
  60. Flanagan EP, Geschwind MD, Lopez-Chiriboga AS et al. Autoimmune encephalitis misdiagnosis in adults. JAMA Neurol. 2023;80(1):30–39. doi: 10.1001/jamaneurol.2022.4251.
  61. Hébert J, Muccilli A, Wennberg RA. Autoimmune encephalitis and autoantibodies: A review of clinical implications. J Appl Lab Med. 2022;7(1):81–98. doi: 10.1093/jalm/jfab102.
  62. Lee S, Kim HD, Lee JS et al. Clinical features and treatment outcomes of seronegative pediatric autoimmune encepha-litis. J Clin Neurol. 2021;17(2):300–306. doi: 10.3988/jcn.2021.17.2.300.
  63. Hayashi K, Hikiji W, Makino Y, Suzuki H. An autopsy case of suspected anti-N-methyl-D-aspartate receptor encephalitis. J Forensic Sci Med. 2019;5:213–216. doi: 10.4103/jfsm.jfsm_59_18.
  64. Tüzün E, Zhou L, Baehring JM et al. Evidence for antibody-mediated pathogenesis in anti-NMDAR encephalitis associated with ovarian teratoma. Acta Neuropathol. 2009;118(6):737–743. doi: 10.1007/s00401-009-0582-4.
  65. Dao LM, Machule ML, Bacher P et al. Decreased inflammatory cytokine production of antigen-specific CD4+ T cells in NMDA receptor encephalitis. J Neurol. 2021;268(6):2123–2131. doi: 10.1007/s00415-020-10371-y.
  66. Gillinder L, Warren N, Hartel G et al. EEG findings in NMDA encephalitis — A systematic review. Seizure. 2019;65:20–24. doi: 10.1016/j.seizure.2018.12.015.
  67. Faraguna U, Vyazovskiy VV, Nelson AB et al. A causal role for brain-derived neurotrophic factor in the homeostatic regulation of sleep. J Neurosci. 2008;28(15):4088–40895. doi: 10.1523/JNEUROSCI.5510-07.2008.
  68. Harmony T. The functional significance of delta oscillations in cognitive processing. Front Integr Neurosci. 2013;7:83. doi: 10.3389/fnint.2013.00083.
  69. Steriade M, McCormick DA, Sejnowski TJ. Thalamocortical oscillations in the sleeping and aroused brain. Science. 1993;262(5134):679–685. doi: 10.1126/science.8235588.
  70. Nabizadeh F, Ramezannezhad E, Sardaripour A et al. [18F] FDG brain PET and clinical symptoms in different autoantibodies of autoimmune encephalitis: A systematic review. Neurol Sci. 2022;43(8):4701–4718. doi: 10.1007/s10072-022-06094-9.
  71. Jabs BE, Pfuhlmann B, Bartsch AJ, Cetkovich-Bakmas MG, Stöber G. Cycloid psychoses — from clinical concepts to biologi-cal foundations. J Neural Transm (Vienna). 2002;109:907–919. doi: 10.1007/s007020200074.
  72. Martinez-Hernandez E, Horvath J, Shiloh-Malawsky Y et al. Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis. Neurology. 2011;77(6):589–593. doi: 10.1212/WNL.0b013e318228c136.
  73. Dietl HW, Pulst SM, Engelhardt P, Mehraein P. Paraneoplastic brainstem encephalitis with acute dystonia and central hypoventilation. J Neurol. 1982;227(4):229–238. doi: 10.1007/BF00313390.
  74. Lu T, Cai W, Qiu W et al. Brainstem and vestibulocochlear nerve involvement in relapsing-remitting anti-NMDAR encephalitis. Neurol Sci. 2016;37(1):149–151. doi: 10.1007/s10072-015-2385-9.
  75. Schäbitz WR, Rogalewski A, Hagemeister C, Bien CG. VZV brainstem encephalitis triggers NMDA receptor immunoreaction. Neurology. 2014;83(24):2309–2311. doi: 10.1212/WNL.0000000000001072.
  76. Wang HY, Li T, Li XL et al. Anti-N-methyl-D-aspartate receptor encephalitis mimics neuroleptic malignant syndrome: Case report and literature review. Neuropsychiatr Dis Treat. 2019;15:773–778. doi: 10.2147/NDT.S195706.
  77. Young D. The NMDA receptor antibody paradox: A possible approach to developing immunotherapies targeting the NMDA receptor. Front Neurol. 2020;11:635. doi: 10.3389/fneur.2020.00635.
  78. Bacherikov NE, Petlenko VP, Shcherbina EA. Filosofskie voprosy psikhiatrii. Kiev: Zdorovya; 1985. 192 с. (In Russ).
  79. Nuller YuL, Mikhalenko IN. Affektivnye psikhozy. Leningrad: Meditsina; 1988. 264 p. (In Russ.)
  80. Smirnov VK. Psikhogigiena i psikhicheskoe zdorov’e. In: Psikhicheskoe zdorov’e i pogranichnye sostoyaniya. Sb. nauch. tr. Pod obshch. red. V.K. Smirnova. Gor’kii: GMI; 1983:38–58. (In Russ)

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».